H. Lundbeck A/S

143 articles about H. Lundbeck A/S

• H. Lundbeck A/S And Takeda Receive Complete Response Letter From The FDA For Trintellix (Vortioxetine) Snda

  6/23/2017

• H. Lundbeck A/S Obtains Rights To Breakthrough Research In Alzheimer’s Disease

  6/6/2017

• Transactions With Shares And Linked Securities In H. Lundbeck A/S Made By Executives And Their Closely Associated Parties

  5/24/2017

• H. Lundbeck A/S Release: 2017 Guidance Raised Based On Strong Revenue Growth And Improved Profitability

  5/10/2017

• H. Lundbeck A/S Gets $55.6 Million From Sale Of Part Of Its HQ

  5/5/2017

• H. Lundbeck A/S Throws in the Towel on Alzheimer's Pill, Giving Leeway to Rival Axovant

  2/8/2017

• Ossianix Release: Company Receives Milestone Payment From H. Lundbeck A/S For Blood-Brain Barrier (BBB) Antibody Delivery Technology

  1/26/2017

• Otsuka Pharmaceutical Development & Commercialization, Inc. And H. Lundbeck A/S Present Data At ACNP Annual Meeting On Long-Acting Injectable Aripiprazole As A Potential Maintenance Treatment For Bipolar I Disorder

  12/7/2016

• H. Lundbeck A/S's Phase III Data Crushes Hope for Alzheimer’s Once Again

  9/23/2016

• Patient Groups Rank Lundbeck US First In Corporate Reputation Among Top Pharmaceutical Companies

  4/7/2016

• H. Lundbeck A/S Falls After FDA Rejects Brintellix Label Expansion

  3/29/2016

• Agilis Biotherapeutics Names Former H. Lundbeck A/S Executive, Christopher J. Silber, MD, As Chief Medical Officer

  1/25/2016

• H. Lundbeck A/S Release: Largest Prospective Study Evaluating The Effect Of Vigabatrin On Vision

  11/25/2015

• H. Lundbeck A/S: Experts Call For Urgent Action To Better Diagnose Severe Form Of Bipolar I Disorder, Which Is Costing Healthcare Economies Billions1,2

  8/31/2015

• H. Lundbeck A/S Slashing 1,000 Employees as Company Faces Declining Revenue Due to Generic Competition

  8/20/2015

• H. Lundbeck A/S Joins Innovative Alzheimer’s Disease Research Initiative

  8/7/2015

• Otsuka Pharma, H. Lundbeck A/S Beat Competitors With FDA Approval of Schizophrenia Drug

  7/13/2015

• H. Lundbeck A/S and Otsuka America Pharmaceutical, Inc. Release: Results Of Phase III Study Of Brexpiprazole In Adult Patients With Schizophrenia Published In American Journal Of Psychiatry

  4/17/2015

• H. Lundbeck A/S And Ovid Therapeutics Announce Exclusive Worldwide Licensing Agreement For Gaboxadol

  4/16/2015

• H. Lundbeck A/S And ‘Keep Memory Alive’ Invest To Support Multiple System Atrophy Research And Global Taskforce

  4/14/2015